We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Cookie Policy

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

You are Here
Novavax says new data shows effectiveness of updated Covid-19 jab
Health

Novavax says new data shows effectiveness of updated Covid-19 jab

US vaccine maker Novavax mentioned on Monday that new knowledge from Novavax’s ongoing analysis on its up to date XBB.1.5 Covid-19 vaccine in contributors who beforehand acquired an mRNA vaccine confirmed strong neutralizing antibody titers for the XBB.1.5 subvariant in addition to for the presently circulating JN.1 subvariant.

The knowledge additionally confirmed that the vaccine’s security and reactogenicity profile was in line with its prototype vaccine (NVX-CoV2373).

Source: www.anews.com.tr

Share
Facebook Twitter Pinterest Linkedin

Related Posts